The JAK-STAT pathway: Impact on human disease and therapeutic intervention

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 311-328

  O'Shea, John J ^a   Schwartz, Daniella M ^a   Villarino, Alejandro V ^a   Gadina, Massimo ^a   McInnes, Iain B ^a   Laurence, Arian ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

autoimmunity; cancer; cytokine; immunodeficiency; kinase inhibitors

Indexed keywords

JANUS KINASE; OCLACITINIB; RUXOLITINIB; STAT PROTEIN; STAT2 PROTEIN; TOFACITINIB;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GROWTH RETARDATION; HUMAN; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; MUCOCUTANEOUS CANDIDIASIS; NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; JANUS KINASES; NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84921325808     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051113-024537     Document Type: Article

References (88)

1. O'Shea JJ, Holland SM, Staudt LM. 2013. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368:161-70
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346:1185-93
3. Rivat C, Santilli G, Gaspar HB, Thrasher AJ. 2012. Gene therapy for primary immunodeficiencies. Hum. Gene Ther. 23:668-75
4. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-56
5. Minegishi Y, SaitoM, Tsuchiya S, et al. 2007. Dominant-negativemutations in theDNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058-62
6. Holland SM, DeLeo FR, Elloumi HZ, et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:1608-19
7. Casanova JL, Holland SM, Notarangelo LD. 2012. Inborn errors of human JAKs and STATs. Immunity 36:515-28
8. Miossec P, Kolls JK. 2012. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11:763-76
9. Durant L, Watford WT, Ramos HL, et al. 2010. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32:605-15
10. CiofaniM, Madar A, Galan C, et al. 2012. A validated regulatory network for Th17 cell specification. Cell 151:289-303
11. Sonnenberg GF, Fouser LA, Artis D. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12:383-90
12. Mogensen TH. 2013. STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT 2:e23435
13. Siegel AM, Heimall J, Freeman AF, et al. 2011. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35:806-18
14. Steward-Tharp SM, Laurence A, Kanno Y, et al. 2014. A mouse model of HIES reveals pro-And antiinflammatory functions of STAT3. Blood 123:2978-87
15. Uzel G, Sampaio EP, Lawrence MG, et al. 2013. Dominant gain-of-function STAT1 mutations in FOXP3 wild-Type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J. Allergy Clin. Immunol. 131:1611-23
16. Minegishi Y, SaitoM, Morio T, et al. 2006. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745-55
17. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. 2012. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J. Pediatr. 160:1055-57
18. Hambleton S, Goodbourn S, Young DF, et al. 2013. STAT2 deficiency and susceptibility to viral illness in humans. Proc. Natl. Acad. Sci. USA 110:3053-58
19. LeonardWJ, O'Shea JJ. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322
20. Cohen AC, Nadeau KC, Tu W, et al. 2006. Cutting edge: decreased accumulation and regulatory function of CD4+CD25high T cells in human STAT5b deficiency. J. Immunol. 177:2770-74
21. Semple JW. 2008. ITP three R's: regulation, routing, rituximab. Blood 112:927-28
22. Hand TW, Cui W, Jung YW, et al. 2010. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl. Acad. Sci. USA 107:16601-6
23. Levine RL, Gilliland DG. 2008. Myeloproliferative disorders. Blood 112:2190-98
24. Spivak JL. 2010. Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations: the phenotypic mimicry of chronic myeloproliferation. Ann. Intern. Med. 152:300-6
25. Ungureanu D, WuJ, Pekkala T, et al. 2011. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18:971-76
26. Bandaranayake RM, Ungureanu D, Shan Y, et al. 2012. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19:754-59
27. Zhang Y, Kolesar JM. 2011. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Clin. Ther. 33:1560-76
28. Tefferi A. 2008. JAK and MPL mutations in myeloid malignancies. Leuk. Lymphoma 49:388-97
29. Scott LM. 2011. The JAK2 exon 12 mutations: a comprehensive review. Am. J. Hematol. 86:668-76
30. Nielsen C, Birgens HS, Nordestgaard BG, et al. 2011. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96:450-53
31. Xiang Z, Zhao Y, Mitaksov V, et al. 2008. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 111:4809-12
32. Sakaguchi H, Okuno Y, Muramatsu H, et al. 2013. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45:937-41
33. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9:798-809
34. Song JI, Grandis JR. 2000. STAT signaling in head and neck cancer. Oncogene 19:2489-95
35. Kryczek I, Lin Y, Nagarsheth N, et al. 2014. IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40:772-84
36. Lam LT, Wright G, Davis RE, et al. 2008. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-?B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-13
37. Koskela HL, Eldfors S, Ellonen P, et al. 2012. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366:1905-13
38. Jerez A, Clemente MJ, Makishima H, et al. 2012. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders ofNKcells andT-cell large granular lymphocyte leukemia. Blood 120:3048-57
39. Jerez A, Clemente MJ, Makishima H, et al. 2013. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 122:2453-59
40. Ishida F, Matsuda K, Sekiguchi N, et al. 2014. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 105:342-46
41. Rajala HL, Eldfors S, Kuusanmaki H, et al. 2013. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121:4541-50
42. Nelson EA, Walker SR, Weisberg E, et al. 2011. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117:3421-29
43. Dunn GP, Koebel CM, Schreiber RD. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-48
44. Chan SR, Rickert CG, Vermi W, et al. 2014. Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα+ tumorigenesis. Cell Death Differ. 21:234-46
45. Chen E, Beer PA, Godfrey AL, et al. 2010. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18:524-35
46. Butterbach K, Beckmann L, de Sanjose S, et al. 2011. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph). Br. J. Haematol. 153:318-33
47. Ellinghaus D, Ellinghaus E, Nair RP, et al. 2012. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 90:636-47
48. Remmers EF, Plenge RM, Lee AT, et al. 2007. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357:977-86
49. DuetschG, Illig T, Loesgen S, et al. 2002. STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study. Hum. Mol. Genet. 11:613-21
50. Macchi P, Villa A, Giliani S, et al. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:65-68
51. Russell SM, Tayebi N, Nakajima H, et al. 1995. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270:797-800
52. Riese RJ, Krishnaswami S, Kremer J. 2010. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract. Res. Clin. Rheumatol. 24:513-26
53. Clark JD, Flanagan ME, Telliez J-B. 2014. Discovery and development of Janus kinase ( JAK) inhibitors for inflammatory diseases. J. Med. Chem. 57:5023-38
54. Kudlacz E, Perry B, Sawyer P, et al. 2004. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transpl. 4:51-57
55. Kremer JM, Bloom BJ, Breedveld FC, et al. 2009. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum. 60:1895-905
56. Tanaka Y, Suzuki M, Nakamura H, et al. 2011. Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. (Hoboken) 63:1150-58
57. Kremer JM, Cohen S, Wilkinson BE, et al. 2012. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64:970-81
58. Fleischmann R, Cutolo M, Genovese MC, et al. 2012. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64:617-29
59. Burmester GR, Blanco R, Charles-Schoeman C, et al. 2013. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451-60
60. van der Heijde D, Tanaka Y, Fleischmann R, et al. 2013. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 65:559-70
61. Lee EB, Fleischmann R, Hall S, et al. 2014. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370:2377-86
62. Vincenti F, Tedesco SilvaH, Busque S, et al. 2012. Randomized phase 2b trial of tofacitinib (CP-690, 550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.Am. J. Transpl. 12:2446-56
63. Liew SH, Nichols KK, Klamerus KJ, et al. 2012. Tofacitinib (CP-690, 550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology 119:1328-35
64. Papp KA, Menter A, Strober B, et al. 2012. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 167:668-77
65. Strober B, Buonanno M, Clark JD, et al. 2013. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br. J. Dermatol. 169:992-99
66. PortsWC, Khan S, Lan S, et al. 2013. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br. J. Dermatol. 169:137-45
67. Mamolo C, Harness J, Tan H, Menter A. 2013. Tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-To-severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 28:192-203
68. Menter A, Papp KA, Tan H, et al. 2014. Efficacy of tofacitinib, an oral Janus kinase inhibitor, on clinical signs of moderate-To-severe plaque psoriasis in different body regions. J. Drugs Dermatol. 13:252-56
69. SandbornWJ, Ghosh S, Panes J, et al. 2012. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367:616-24
70. SandbornWJ, Ghosh S, Panes J, et al. 2014. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 12:1485-93
71. Craiglow BG, King BA. 2014. Killing two birdswith one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J. Invest. Dermatol. 134:2988-90
72. Xing L, Dai Z, Jabbari A, et al. 2014. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 20:1043-49
73. Fleischmann R, Kremer J, Cush J, et al. 2012. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367:495-507
74. Kremer JM, Li Z-G, Hall S, et al. 2011. Tofacitinib (CP-690, 550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann. Rheum. Dis. 70:170
75. van Vollenhoven RF, Fleischmann R, Cohen S, et al. 2012. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367:508-19
76. Lee EB, Fleischmann R, Hall S. 2012. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-na'ive patients with rheumatoid arthritis. Arthritis Rheum. 64:S1049
77. He Y, Wong AY, Chan EW, et al. 2013. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-Analysis. BMC Musculoskelet. Disord. 14:298
78. Winthrop KL, Yamanaka H, Valdez H, et al. 2014. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 66:2675-84
79. Wollenhaupt J, Silverfield J, Lee EB, et al. 2014. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J. Rheumatol. 41:837-52
80. Cohen S, Radominski SC, Gomez-Reino JJ, et al. 2014. Analysis of infections and all-cause mortality in Phase II, III and long-Term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 66:2924-37
81. Rao VU, Pavlov A, Klearman M, et al. 2012. Risk factors for major adverse cardiovascular events in rheumatoid arthritis patients treated with the interleukin-6 receptor inhibitor tocilizumab. J. Am. Coll. Cardiol. 59:E1648
82. Cosgrove SB, Wren JA, Cleaver DM, et al. 2013. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (ApoquelR-) in client-owned dogs with atopic dermatitis. Vet. Dermatol. 24:587-97, e141-42
83. Pardanani A, Gotlib K, Gupta V, et al. 2013. Update on the long-Term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 122:108
84. Strand V, Suthoff E, Fleischmann R, et al. 2013. Effects of VX-509, an investigational oral selective Janus kinase 3 ( JAK3) inhibitor, on patient-reported outcomes in a phase 2A study of patients with active rheumatoid arthritis. Arthritis Rheum. 65:S1004-S5
85. Tasset C, Harrison P, Van der Aa A, et al. 2013. The JAK1-selective inhibitor GLPG0634 is safe and rapidly reduces disease activity in patients withmoderate to severe rheumatoid arthritis; results of a 4-week dose ranging study. Arthritis Rheum. 65:S1018
86. Vanhoutte F, MazurM, Van derAaA, et al. 2012. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum. 64:S1051
87. Park J-S, Kwok S-K, Lim M-A, et al. 2014. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis. Arthritis Rheumatol. 66:918-29
88. Koo MY, Park J, Lim JM, et al. 2014. Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody. Proc. Natl. Acad. Sci. USA 111:6269-74